Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?

Carla Silva, Elizabeth Ianna, Tracey Jones, Joshua Davis

    Research output: Contribution to journalComment/debate

    Fingerprint

    Dive into the research topics of 'Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?'. Together they form a unique fingerprint.

    Medicine & Life Sciences